Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Central Pain Study for ABX-1431

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03138421
Recruitment Status : Completed
First Posted : May 3, 2017
Last Update Posted : January 25, 2019
Sponsor:
Information provided by (Responsible Party):
Abide Therapeutics

Brief Summary:

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.

During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.


Condition or disease Intervention/treatment Phase
Neuromyelitis Optica Spectrum Disorder Transverse Myelitis Multiple Sclerosis Longitudinally Extensive Transverse Myelitis Drug: ABX-1431 HCl Drug: Placebo Phase 1

Detailed Description:

This is a double-blind, placebo-controlled crossover study, randomized, crossover study of ABX-1431 HCl as add-on therapy in the treatment of central neuropathic pain.The efficacy of ABX-1431 will also be assessed by the change in pain intensity scores using a numerical rating scale (NRS-11).

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 7 to 9 weeks, which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will use a web based application to record their daily average pain using a numerical rating scale (NRS-11).

This study will enroll up to 32 patients with chronic central pain due to one of the four following diagnostic groups: Neuromyeliltis Optica Spectrum Disorder (NMOSD), longitudinally extensive transverse myelitis (LETM), Multiple Sclerosis (MS), and Transverse Myelitis (TM).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : July 23, 2018
Actual Study Completion Date : July 24, 2018


Arm Intervention/treatment
Experimental: ABX-1431 HCl Drug: ABX-1431 HCl
ABX-1431 HCl, capsules, 20 mg

Placebo Comparator: Placebo Drug: Placebo
Matching placebo




Primary Outcome Measures :
  1. Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale [ Time Frame: placebo, treatment (14 days) ]
    The treatment difference of ABX-1431 HCl versus placebo is estimated from the change from baseline in daily NRS-11 Pain to the final 7 days of treatment in each two-week treatment period. Baseline levels of pain or taken from the final 7 days of treatment in the period preceding each double-blind treatment period.


Secondary Outcome Measures :
  1. Short Form Brief Pain Inventory (SF-BPI) Scores [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  2. Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  3. Patient Global Impression of Change (PGIC) score [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  4. Proportion of patients achieving and maintaining >30%, >50%, reduction in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  5. Actigraphically estimated parameters of sleep (WASO, TST, sleep efficiency, average overnight activity counts) and general activity measured by percentage of sedentary time, and moderate to high intensity activity [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  6. Sleep interference (NRS-11) A NRS-11 scale recording sleep interference due to transverse myelitis pain / central pain in the previous week (in which 0 = no interference and 10 = greatest possible interference) [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  7. ABX-11431 and metabolite M55 plasma PK [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo

  8. 2-AG hydrolysis in PBMC [ Time Frame: placebo, treatment (14 days) ]
    Difference in the change from baseline between ABX-1431 HCl and placebo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with chronic central pain, present for at least 3 months due to one of the four following diagnostic groups: NMOSD, LETM, MS, or TM.

    • Patient has a diagnosis of NMOSD with anti-AQP4 IgG or without AQP4-IgG as defined by the International Panel for NMO Diagnosis at least 3 months prior to the screening visit (IPND 2015)
    • Patients with idiopathic, LETM, comprising an intramedullary MRI lesion or continuous segments of spinal cord atrophy with a clinical history consistent with acute myelitis, and with chronic pain syndrome consistent with the lesion neuroanatomy may be enrolled. These LETM patients must also demonstrate evidence of acute, inflammatory myelopathy in the past (e.g. clinically acute symptomatic myelitis plus inflammatory CSF analysis (e.g. elevated WBC and IgG index) or imaging consistent with inflammatory myelopathy). LETM must be diagnosed at least 3 months prior to the screening visit.
    • Patient with MS defined by McDonald criteria [1] or Poser criteria [2] at least 3 months prior to screening visit.
    • Patients with post-infectious, autoimmune or idiopathic TM diagnosed by a neurologist at least 6 months prior to the screening visit.
  • Patient's chronic pain must be neuropathic in nature, and anatomically plausible based on underlying neuropathology. If patient has an additional source of pain (e.g., vascular ischemic pain, transient spasm associated pain, headache, chronic lower back pain or concomitant osteoarthritic joint pain), the central neuropathic pain must be clearly identifiable by the patient, as assessed by the Investigator.
  • The Investigator determines that the patient can enter daily NRS-11 pain intensity data on an internet connected device such as a smart phone, tablet computer or desktop computer with reliable internet service. Patients that do not have a device will be supplied one for the duration of the study. At the direction of the patient, the patient's caregivers may enter the pain intensity data.
  • At Visit 2, patient's pain is ≥ 4 on the NRS-11 pain intensity scale, on at least 4 of the 7 days preceding randomization.
  • Patients taking immunosuppressive therapy (IST) for relapse prevention of NMOSD or TM or taking disease modifying therapy (DMT) for MS must be on a stable maintenance dose(s) of IST or DMT for 30 days prior to screening and must be expected to maintain the IST or DMT regimenduring this study.
  • Patients taking oral corticosteroids must be on a stable dose of medication for at least one week before study start and must be expected to remain on a stable dose during this study. The dose may be no more than prednisolone 20 mg daily or equivalent.
  • For patients taking antibody therapy for NMOSD relapse prevention (e.g. rituximab, eculizumab or tocilizumab), therapy must be discontinued at least 6 months prior to screening and patients must be willing to refrain from use during this study.
  • Patients taking daily neuropathic or central pain medications (e.g. gabapentin, amitriptyline, lamotrigine) must be on a stable dose of medication for 30 days before study start and must be expected to remain on a stable dose during this study.
  • Patients must give written informed consent.
  • Patients must be willing and able to comply with the protocol requirements for the duration of the study.
  • Female patients of child-bearing potential must have a negative pregnancy test [serum human chorionic gonadotropin (HCG)]. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (i.e. theoretical failure rate less than 1% per year including oral or parenteral hormonal contraception, Nuvaring, intrauterine device (IUD) or male condom plus spermicide). Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with historical documentation of surgical procedure and a negative pregnancy test.
  • Male patients must be willing to use a condom with sexual partners during this study until the poststudy visit. Male patients must be willing to abstain from sperm donation for 3 months after the completion of this study.

Exclusion Criteria:

  • Patients with chronic central pain due to trauma, vascular causes, active infection, neoplasm, radiation, metabolic, toxic or other non-inflammatory brain disease or myelopathy are excluded. Patients with trigeminal neuralgia, either as an isolated condition or with MS are excluded. Patients with a history of encephalitis are excluded. Patients with systemic inflammatory autoimmune disorders associated with TM are excluded (e.g. sarcoidosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's Syndrome, rheumatoid arthritis). TM secondary to infection of the nervous system is excluded (e.g. herpes virus, Lyme disease). TM associated with HIV infection is excluded.
  • Patient has an onset of an MS, LETM or TM relapse or NMOSD acute episode within 60 days before the study start.
  • Patients with unresolved infections, AIDS myelopathy, or degenerative neurological conditions.
  • Patient has received the following within 60 days before study start:

    • Intrathecal baclofen.
    • Injection therapies such a botulinum toxin, anesthetic or nerve block to control pain.
    • Plasma exchange
  • Patients taking daily oral opioid drugs are excluded.
  • Patient is taking carbamazepine or oxcarbazine or eslicarbazepine or other potent cytochrome P450 3A4/5 inducers [e.g. rifampin, St. John's Wort (Hypericum perforatum), phenytoin]. Patient is taking strong P450 3A4/5 inhibitors including atazanavir, bocepravir, clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, or voriconazole.
  • Patient has evidence of alcohol, drug or chemical abuse, at study start or within 1 year before the study start.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03138421


Locations
Layout table for location information
United Kingdom
The Walton Centre
Liverpool, United Kingdom, L97LJ
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
Abide Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Jacqueline Palace, FRCP DM Oxford University Hospitals NHS Trust
Principal Investigator: Anu Jacob, MD DM FRCP The Walton Centre

Layout table for additonal information
Responsible Party: Abide Therapeutics
ClinicalTrials.gov Identifier: NCT03138421     History of Changes
Other Study ID Numbers: ABX-1431_PN009
First Posted: May 3, 2017    Key Record Dates
Last Update Posted: January 25, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromyelitis Optica
Paraneoplastic Syndromes, Nervous System
Paraneoplastic Syndromes
Myelitis, Transverse
Multiple Sclerosis
Myelitis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Central Nervous System Infections
Central Nervous System Diseases
Spinal Cord Diseases
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Neurodegenerative Diseases